Vizamyl Clinical Development
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A timeline chronicling the development history of GE Healthcare’s Flutemetamol F 18 and the regulatory path of radioactive diagnostic agents for PET imaging of the brain to estimate beta amyloid neuritic plaque density.